Clomacran

CHEMBL1615350 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

300.8 g/mol

LogP

4.6

Phase

4

An antipsychotic agent belonging to the phenothiazine class used to treat psychiatric conditions. It helps manage symptoms such as hallucinations and disordered thinking.

Masse moléculaire

300,8000 g/mol

LogP

4,60

TPSA

15,30 Å²

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN(C)CCCC1c2ccccc2Nc2ccc(Cl)cc21

InChI

InChI=1S/C18H21ClN2/c1-21(2)11-5-7-14-15-6-3-4-8-17(15)20-18-10-9-13(19)12-16(14)18/h3-4,6,8-10,12,14,20H,5,7,11H2,1-2H3

Molecular Formula

C18H21ClN2

HBD / HBA

1 / 2

Liaisons Rotatives

4

Atomes Lourds

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

An antipsychotic agent belonging to the phenothiazine class used to treat psychiatric conditions. It helps manage symptoms such as hallucinations and disordered thinking.

Blocks dopamine D2 receptors in the mesolimbic pathway, reducing excessive dopaminergic neurotransmission associated with psychotic symptoms. Many also antagonize serotonin 5-HT2A receptors, which may improve negative symptoms and reduce extrapyramidal side effects.

Yes, Clomacran is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1615350. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 21382. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Clomacran sur PillFYI

Structure

Données Clés

Formule: C18H21ClN2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.